2022-11-07 14:00
The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 7 November 2022 in Stockholm and the following resolutions were passed by the meeting. RIGHTS ISSUE The extra general meeting resolved...
2022-10-20 08:00
Biovica, active in cancer diagnostics, today announces that Anders Morén has been appointed as the company’s Chief Financial Officer (CFO). Anders Morén will begin his new position on January 1, 2023. Most recently, Anders Morén...
2022-10-19 08:00
Biovica today announces that the company has submitted its CLIA lab application, marking yet another significant milestone for the US commercial launch of the recent FDA cleared test DiviTum®TKa. Biovica is now prepared to receive, analyze, and report...
2022-10-18 08:45
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Monday 7 November 2022, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises...
2022-10-18 08:42
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION...
2022-08-31 16:10
The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 31 August 2022 and the following resolutions were passed by the meeting. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEET The annual...
2022-08-31 08:00
Significant events during the first quarter · Results with DiviTum®TKa at ASCO · DiviTum®TKa highlighted at ASCO in an oral presentation · Biovica’s CFO will terminate employment in December 2022 ·...
2022-08-15 15:00
Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa’s US market approval received on July 29 from the US Food and Drug Administration (FDA). At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander...
2022-07-30 13:00
Biovica, active in cancer diagnostics, today announces that FDA has granted 510(k) clearance for the product DiviTum®TKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female...
2022-07-27 08:00
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting on Wednesday 31 August 2022. The board of directors has decided that the annual general meeting shall only be...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects